Literature DB >> 33205966

Living Therapeutics: The Next Frontier of Precision Medicine.

Vince W Kelly1, Benjamin K Liang1, Shannon J Sirk1.   

Abstract

Modern medicine has long studied the mechanism and impact of pathogenic microbes on human hosts, but has only recently shifted attention toward the complex and vital roles that commensal and probiotic microbes play in both health and dysbiosis. Fueled by an enhanced appreciation of the human-microbe holobiont, the past decade has yielded countless insights and established many new avenues of investigation in this area. In this review, we discuss advances, limitations, and emerging frontiers for microbes as agents of health maintenance, disease prevention, and cure. We highlight the flexibility of microbial therapeutics across disease states, with special consideration for the rational engineering of microbes toward precision medicine outcomes. As the field advances, we anticipate that tools of synthetic biology will be increasingly employed to engineer functional living therapeutics with the potential to address longstanding limitations of traditional drugs.

Entities:  

Keywords:  living therapeutics; microbial engineering; microbiota; synthetic biology

Mesh:

Substances:

Year:  2020        PMID: 33205966     DOI: 10.1021/acssynbio.0c00444

Source DB:  PubMed          Journal:  ACS Synth Biol        ISSN: 2161-5063            Impact factor:   5.110


  2 in total

Review 1.  Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.

Authors:  Jason P Lynch; Lisa Goers; Cammie F Lesser
Journal:  Trends Pharmacol Sci       Date:  2022-02-26       Impact factor: 17.638

2.  Efficient markerless integration of genes in the chromosome of probiotic E. coli Nissle 1917 by bacterial conjugation.

Authors:  Elena M Seco; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2021-11-09       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.